You are here
Alphatec to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
CARLSBAD, Calif., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (“Alphatec” or the “Company”) (Nasdaq: ATEC), a provider of innovative spine surgery solutions with a mission to improve patient lives through the relentless pursuit of superior outcomes, today announced that Terry Rich, President and Chief Operating Officer, will present at the Rodman & Renshaw 20th Annual Global Investment Conference at 12:30 p.m. ET on Thursday, September 6, 2018 in New York, NY.
A live webcast of the presentation will be available online on the “Investor Relations” page of the Company’s website at www.atecspine.com. A replay of the presentation will be available on the same site for 90 days following the webcast.
Additional information can be found at www.atecspine.com.
Statements made in this press release and made during the investor events referenced herein may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to many risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Forward-looking statements include the references to the Company’s strategy in significantly repositioning the Alphatec brand and turning the Company into a growing organization. The important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the uncertainties regarding the Company’s ability to recognize the expected synergies and other benefits of the SafeOp acquisition;; the uncertainty of success in developing new products or products currently in the Company’s pipeline; the uncertainties in the Company’s ability to execute upon its strategic operating plan; the uncertainties regarding the ability to successfully license or acquire new products, and the commercial success of such products; failure to achieve acceptance of the Company’s products by the surgeon community, including Battalion and Arsenal Deformity; failure to obtain FDA or other regulatory clearance or approval for new products, or unexpected or prolonged delays in the process; continuation of favorable fourth party reimbursement for procedures performed using the Company’s products; unanticipated expenses or liabilities or other adverse events affecting cash flow or the Company’s ability to successfully control its costs or achieve profitability; uncertainty of additional funding; the Company’s ability to compete with other competing products and with emerging new technologies; product liability exposure; an unsuccessful outcome in any litigation in which the Company is a defendant; patent infringement claims; claims related to the Company’s intellectual property and the Company’s ability to meet its financial obligations under its credit agreements and the Orthotec settlement agreement. A further list and description of these and other factors, risks and uncertainties can be found in the Company’s most recent annual report, and any subsequent quarterly and current reports, filed with the Securities and Exchange Commission. Alphatec disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise unless required by law.
Executive Vice President and Chief Financial Officer
Alphatec Holdings, Inc.